临床上，往往会采用"新四联"或"五联"药物方案来延缓重塑进展，但效果有限，很多冠心病、高血压心 脏病、糖尿病、心肌病等患者，心脏仍在继续扩大，心功能持续下降，最终进展为心力衰竭。心力衰竭 患者的生活质量严重下降，晚期患者常常躺不平、稍动即喘，下肢水肿难以消退，甚至因肠道淤血影响 进食，陷入"药效不佳、病情进展"的恶性循环。 面对西医治疗的局限，王新东团队依托包括9项国家自然科学基金和2项江苏省自然科学基金在内的多项 课题支持，从三个维度展开深入研究，为中西医结合方案提供了坚实的科学支撑。 在临床层面，团队通过长期随访观察，记录患者心脏大小、射血分数等心功能指标的变化，证实中西医 结合方案至少能让30%以上原本病情进展的患者实现"逆转"——心脏扩大趋势减缓甚至回缩，心功能指 标提升。 在机制研究层面，团队突破传统中医"宏观辨证"的局限，深入分子和细胞层面。一方面，针对心脏细胞 的多种死亡方式（如凋亡、铁死亡等）展开研究，发现中药中的多种成分能精准干预这些病理过程，减 少心肌细胞损伤；另一方面，聚焦心脏离子通道功能，证实中药可调节关键离子平衡，改善心脏电生理 活动，保护心脏功能。 （来源：新华日报） □ 本报记者 ...

【健·真言】 作者：郝美玲、韦企平（分别系北京中医药大学第二临床医学院眼科副主任医师、北京中医药大学第二 临床医学院眼科主任医师） 你是否有过这样的经历？手机看久了眉棱骨痛，头晕恶心入睡困难，眼干眼涩视物模糊，晨起内眦常有 眼屎……这些表现，其实是眼睛在"求救"。 作为"数字时代病"，干眼与视疲劳困扰着超过60%的都市人群，上述症状，正是干眼与视疲劳的典型信 号，而长期使用电子设备、空调环境、隐形眼镜佩戴不当等是主要诱因。 干眼常伴随视疲劳出现，表现为眼干、异物感、视物模糊、畏光、隐形眼镜佩戴后眼痛不适等症状，严 重时还会影响角膜健康。这类"视觉亚健康"人群不妨试试中西医结合的治疗方法。 干眼大致可分泪液缺乏型和蒸发过强型两种类型。 泪液缺乏型干眼可根据患者病情，选择泪液补充、保存、刺激分泌、抗炎等不同疗法，对于药物治疗无 效者可行泪点栓塞术；蒸发过强型干眼，主要原因是睑板腺功能障碍，睑缘炎也可导致泪液过度蒸发和 泪膜不稳定，使泪液渗透压增加而导致干眼。因此，干眼患者应检查是否有该两种眼表疾病，并及时给 予病因治疗。 中医称干眼为"白涩症"，其病因病机包括:暴风客热或天行赤眼治疗不彻底，余热未消，隐伏肺脾之络 ...

Investment Rating - The report does not explicitly state an investment rating for the gynecological industry or Polycystic Ovary Syndrome (PCOS) treatments Core Insights - Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder among women of reproductive age, characterized by irregular menstruation, hyperandrogenism, and ovulatory dysfunction, with potential metabolic abnormalities such as obesity and insulin resistance [4][10] - The prevalence of PCOS among reproductive-age women in China ranges from 5% to 10%, influenced by diagnostic criteria and regional factors [4][6] - Current treatment options for PCOS include hormonal therapies, insulin sensitizers, and lifestyle modifications, with a focus on managing symptoms and improving fertility outcomes [15][16] Summary by Sections Clinical Manifestations and Epidemiology - PCOS is associated with symptoms such as irregular menstruation, anovulation, hirsutism, and metabolic issues like obesity and insulin resistance [3][4] - Epidemiological studies indicate varying prevalence rates across different regions in China, with notable figures such as 12.8% in Tianjin among adolescents [6] Impact on Fertility - PCOS is a leading cause of anovulatory infertility, with complications including endometrial hyperplasia and increased miscarriage risk due to hormonal imbalances and metabolic dysfunctions [10][11] - Factors contributing to increased miscarriage rates in PCOS patients include obesity, insulin resistance, and hormonal dysregulation [11] Treatment Options - Key medications for PCOS treatment include progestins, oral contraceptives, insulin sensitizers like Metformin, and ovulation induction agents [15] - The report highlights the importance of insurance coverage for these treatments, with various classifications under the national health insurance system [15] Research Progress - Current research focuses on molecular mechanisms of PCOS, including iron death, circadian rhythms, and genetic factors influencing insulin resistance [16] - There is an emphasis on personalized medicine approaches and the integration of traditional Chinese medicine with modern treatments to enhance patient outcomes [16] Implications for Industry Development - The report suggests that the combined treatment strategies for PCOS can guide pharmaceutical companies in developing targeted therapies that address both reproductive and metabolic health [21]

Investment Rating - The report does not explicitly state an investment rating for the gynecological industry or Polycystic Ovary Syndrome (PCOS) treatment sector Core Insights - Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder among women of reproductive age, characterized by irregular menstruation, hyperandrogenism, and ovulatory dysfunction, with potential metabolic abnormalities such as obesity and insulin resistance [4][10] - The prevalence of PCOS among reproductive-age women in China ranges from 5% to 10%, influenced by diagnostic criteria and regional factors [4][6] - Current treatment options for PCOS include hormonal therapies, insulin sensitizers, and lifestyle interventions, with a focus on managing symptoms and improving fertility outcomes [15][16] Summary by Sections Clinical Manifestations and Epidemiology - PCOS is associated with symptoms such as irregular menstruation, anovulation, hirsutism, and metabolic issues like obesity and insulin resistance [3][4] - Epidemiological studies indicate varying prevalence rates across different regions in China, with rates such as 6.5% in Jinan and 12.8% in Tianjin among adolescents [6] Impact on Fertility - PCOS is a leading cause of anovulatory infertility, with approximately 70% of patients experiencing infertility due to anovulation or oligomenorrhea [11] - Long-term anovulation can lead to endometrial hyperplasia and increased risk of endometrial cancer [11] Treatment Options - Key medications for PCOS treatment include progestins, oral contraceptives, insulin sensitizers like Metformin, and ovulation induction agents [15] - The report highlights the classification of these medications under different insurance categories, indicating their coverage status [15] Research Progress - Current research focuses on molecular mechanisms, personalized medicine, and the integration of traditional Chinese medicine with modern treatments for PCOS [16] - Notable areas of exploration include iron death mechanisms, circadian rhythms, and the role of specific biomarkers in predicting insulin resistance and pregnancy outcomes [16] Implications for Industry Development - The combination of Western and traditional Chinese medicine approaches offers insights for pharmaceutical companies to develop multi-target interventions for PCOS [21] - Understanding the interconnectedness of gynecological diseases can guide companies in creating innovative products that address both reproductive and metabolic health [21]

00:21 华声在线12月28日讯（全媒体记者 高煜棋 通讯员 乔木 刘丹 周瑾）看似普通的咳嗽，一拖也可能"致 命"。近日，长沙的张娭毑因咳嗽没有就医，短短几天竟发展成重症肺炎，所幸在湖南中医药大学第二 附属医院（湖南省中医院）中西结合治疗后转危为安。值得一提的是，在张娭毑的救治过程中，中医经 典名方——"千金苇茎汤"的使用，成为逆转危局的关键。 只因咳嗽未就医 几天后竟成重症肺炎 今年11月，87岁的张娭毑在家出现咳嗽、乏力等症状，没有引起重视，并未进行处理和就医。没想到仅 几天后，她就出现了咳痰不出、呼吸困难等情况，被送入医院进行治疗。其肺部CT提示，张娭毑的双 肺感染面积达30%，指脉血氧饱和度最低降至80%，炎症指标明显升高，已出现Ⅱ型呼吸衰竭，随时存 在生命危险。 从普通咳嗽到重症肺炎，为何张娭毑的病情会进展如此迅速？ "很多患者最初只是普通感染，但由于拖延、硬扛，最终发展为重症肺炎、呼吸衰竭，甚至多器官功能 衰竭。"湖南中医药大学第二附属医院重症医学科（中心ICU）主任、主任医师郑爱华解释，张娭毑年 龄较高，且合并有高血压、冠心病、帕金森、脑梗死、结肠癌等多种基础疾病，肺功能基础较差，早期 未规 ...

对此北京地坛医院中西医结合科主任医师王融冰介绍，第六版诊疗方案重点推荐了清肺排毒汤通治型的 方剂，对中药方剂的煎煮法进行了比较细致的说明，对中药注射剂的使用方法、剂量都有详细说明，使 第六版方案更具有指导性和实用性。 对于中药治疗的疗效，王融冰表示，现在中西医结合的覆盖面非常大，通过前一阶段治疗效果和后一阶 段中药介入后的治疗效果比较，发现中药的参与，中西医结合治疗确实起到比较好的作用。 对于轻症病人，用中药以后迅速改善了发热症状或减轻了咳嗽症状，使其病情不再往重症发展，对于病 人抗病有非常大的助力。对于重症期使用中医药不但可以改善这些症状，对和呼吸相关的指标，比如血 氧饱和度等也有一定改善，这就阻断了病情继续向危重症发展的过程，降低了危重症的发病率，同时也 就等于降低了病死率。 王融冰强调，医学观察期推荐治疗的是有症状的人，"有些人感到虚弱、乏力，甚至有些人有腹泻，我 们推荐了中成药藿香正气水、正气散、正气丸等等。有些觉得自己有点不舒服，甚至有点发热，也推荐 了一些具有清热作用的中成药，这些药物的使用并不是为了预防，所以不主张没有症状的人使用中成药 预防，这没有意义。" 每经记者｜张蕊 每经编辑｜陈旭 2月 ...

Core Insights - Community-acquired pneumonia (CAP) is a common type of lower respiratory tract infection with high incidence and significant harm, particularly among the elderly in China due to the aging population [1][3] Group 1: Disease Characteristics - CAP in the elderly often presents atypical symptoms such as decreased appetite, fatigue, confusion, and urinary incontinence, which can lead to delayed diagnosis [3] - The incidence of elderly CAP shows seasonal fluctuations, with higher rates in Northeast and East China, particularly during autumn and winter [3] - Elderly pneumonia has unique characteristics, including insidious onset, atypical symptoms, rapid progression, and multiple complications [3][4] Group 2: Treatment Approaches - The distribution of pathogens in elderly CAP is characterized by a predominance of Gram-negative bacilli, especially in older patients, with a high risk of mixed infections and antibiotic resistance [4] - Treatment should be based on the unique pathophysiological features of elderly pneumonia, initiating empirical anti-infection therapy early and adjusting treatment based on pneumonia type and severity [4] - New classes of antibiotics can significantly shorten treatment duration and reduce hospital stay, alleviating the healthcare burden [4] Group 3: Prevention Strategies - Vaccination is highlighted as the most cost-effective preventive measure, with recommendations for elderly individuals to receive pneumococcal and seasonal influenza vaccines [6] - Maintaining good hygiene practices, such as handwashing and wearing masks, is essential to reduce infection risk [6] - Additional preventive measures include proper eating posture for those with swallowing difficulties, maintaining oral hygiene, balanced nutrition, and moderate exercise to enhance immunity [6]

Core Insights - The flu activity in China is on the rise, with significant increases in flu-related consultations reported, particularly in southern and northern provinces, indicating a widespread flu epidemic [1] - The demand for antiviral traditional Chinese medicine (TCM) is surging due to the high incidence of respiratory diseases, with hospital visits increasing by approximately 30%-50% year-on-year [3] - The combination of Western and traditional Chinese medicine is becoming a mainstream treatment approach for respiratory infections, leveraging the strengths of both medical systems [4] Industry Demand - The market for antiviral TCM is experiencing a sharp increase in demand, with reports of stock shortages for popular antiviral products in some regions [3][4] - The RSV (Respiratory Syncytial Virus) is prevalent among severe acute respiratory infection cases, particularly in children, creating a complex dual epidemic situation alongside the flu [3] Product Insights - The compound Qilan oral solution, derived from traditional formulations, exhibits both antiviral properties and immune regulation capabilities, making it particularly relevant in the context of mixed infections [5][8] - The product's multi-component and multi-target action mechanism helps regulate immune responses while alleviating core symptoms such as fever and cough [8] Company Operations - Zhenbaodao Pharmaceutical, a leading TCM company, is ramping up production to meet the increasing demand for antiviral products, ensuring a stable supply chain through rigorous quality control measures [8] - The company emphasizes the importance of maintaining high standards in the sourcing and production of raw materials to ensure product efficacy and reliability [8]

Core Insights - The 12th Academic Conference of the Ophthalmology Professional Committee of Hubei Traditional Chinese Medicine Association was held in Enshi City, focusing on the theme "Inheritance and Innovation, Integration for a Bright Future" to promote the development of ophthalmology and traditional Chinese medicine [1][2] Group 1: Conference Highlights - The conference featured renowned experts sharing the latest research findings and clinical experiences, including Professor Kang Zefeng and Professor Xing Yiqiao [1] - An innovative segment titled "Jingming Lunjian: Master’s Diagnosis" allowed ophthalmology experts from various regions to present typical cases and treatment techniques, including a live diagnosis and treatment for a 64-year-old patient [1] Group 2: Educational Initiatives - A "Classics Understanding - Traditional Chinese Ophthalmology Knowledge Competition" was organized to assess participants' understanding of classical literature and clinical applications, enhancing professional skills [2] - In the "Diligent Learning Techniques - New Technology Exchange" section, experts discussed topics such as "Balanced Immunity, Optimal Protection" and "Clinical Application of Integrated Chinese and Western Medicine in Dry Eye Treatment" [2] Group 3: Institutional Progress - Enshi Central Hospital has made significant advancements in medical technology, research innovation, talent cultivation, and service capabilities in ophthalmology, becoming the first national clinical key specialty in the region [2] - The hospital aims to continue enhancing its research and clinical service levels, particularly in areas like myopia prevention, cataract recovery, and refractive surgery, contributing to the health of Enshi and Hubei [2]

Core Insights - A groundbreaking achievement in treating Type 1 diabetes mellitus (T1DM) has been reported by Professor An Chiying and her team at Shenzhen Hengsheng Hospital, where 24 patients have successfully discontinued insulin therapy through holistic integrative medicine (HIM) since June 2024, with the longest insulin-free duration reaching 14 months [1][5] Group 1: Treatment Methodology - The HIM model combines traditional Chinese medicine (TCM), orthomolecular medicine, functional medicine, and lifestyle medicine, focusing on immune blockade and metabolic balance, alongside precision remote digital healthcare to restore islet function [2][3] - The treatment protocol involves multidisciplinary collaboration, including precision diagnostics, immune regulation through molecular nutrition and TCM, metabolic repair via acupuncture and herbal medicine, and precision monitoring using artificial intelligence for personalized treatment adjustments [3] Group 2: Clinical Outcomes - Over a two-year observation period, 70 T1DM patients were treated, with 24 patients (34%) completely discontinuing insulin use while maintaining stable blood glucose levels (HbA1c < 7%) and showing significant recovery of islet function as indicated by C-peptide testing [5][6] - Patients diagnosed early with T1DM and having a C-peptide level above 0.5 ng/ml can stop insulin, while those with lower islet function can significantly reduce insulin dosage once blood glucose levels are stabilized [6] Group 3: Expert Evaluation and Implications - Academician Fan Daiming of the Chinese Academy of Engineering praised the results, stating that they challenge the traditional view of lifelong medication for T1DM and highlight the potential of HIM as a new clinical treatment paradigm [7] - The global T1DM patient population is approximately 9 million, with traditional treatment costs exceeding RMB 10,000 annually, indicating that HIM could alleviate both financial and health burdens on patients [7]